zurück	Radiochemotherapie von HNO-Tumoren
	Studien
Studie	Pat.	Diagnose	RT	Random	PFS	OS
TAX 3235	358	inoperabel	Standard, Hyperfraktioniert, Akzeleriert	Docetaxel, Cisplatin, 5-FU plus RT	11 M	18.8M
				Cisplatin, 5-FU plus RT	8.2M	14.5M
TAX 324	501	inoperabel, z.T. operabel	Standard mit Carboplatin wöchentlich	Docetaxel, Cisplatin, 5-FU plus Radiochemotherapie	36 M	71M
				Cisplatin, 5-FU plus Radiochemotherapie	13M	30M
RTOG-9111	547	Larynx-Ca, inoperabel	Standard mit Carboplatin wöchentlich	Cisplatin plus radiotherapy	47 M	55M
				radiotherapy alone	34M	54M
				cisplatin and fluorouracil plus radiotherapy	45M	59M
Bonner et al.	424	inoperabel, z.T. operabel	Standard, Hyperfraktioniert, Akzeleriert	Cetuximab plus RT	17,1 M	12,4M
				nur RT	49	29,3M
RTOG 9501	459	post OP	Standard	Cisplatin plus radiotherapy	kA	44,9M
				nur RT	kA	31,9M
EORTC 22931	334	post OP	Standard	Cisplatin plus radiotherapy	55M	72M
				nur RT	23M	32M
Quellen	Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to loco-regional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of Chemotherapy on Head Neck Cancer. Lancet. 2000;355:949–955 Pignon JP, Ie Maitre A, Maillard E, et al. MACH-NC Collaborative Group. Meta-analyses of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomized trials and 17,346 patients. Radiother Oncol. 2009;92:4–14

Impressum .....................................................................................Zuletzt geändert am 18.09.2012 4:07